Results 11 to 20 of about 901 (171)

Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study. [PDF]

PLoS ONE, 2022
BackgroundCoronavirus Disease 2019 (COVID-19) is an evolving pandemic that urged the need to investigate various antiviral therapies. This study was conducted to compare efficacy and safety outcomes of darunavir-cobicistat versus lopinavir-ritonavir in ...
Eman Zeyad I Elmekaty, Rim Alibrahim, Rania Hassanin, Sitelbanat Eltaib, Ahmed Elsayed, Fatima Rustom, Mohamed Izham Mohamed Ibrahim, Mohammed Abu Khattab, Hussam Al Soub, Muna Al Maslamani, Abdullatif Al-Khal   +10 more
doaj   +2 more sources

Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS [PDF]

HIV/AIDS: Research and Palliative Care, 2016
Jordi Navarro, Adrian Curran Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain Abstract: Efficacy is the main objective of antiretroviral treatment and adherence is
Navarro J, Curran A
doaj   +3 more sources

Switch from a ritonavir to a cobicistat containing antiretroviral regimen and impact on tacrolimus levels in a kidney transplant recipient

Virology Journal, 2023
Background Solid-organ transplantation due to end-stage organ disease is increasingly performed in people living with HIV. Despite improved transplant outcomes, management of these patients remains challenging due to higher risk for allograft rejection ...
Andrea Erba, Catia Marzolini, Katharina Rentsch, Marcel Stoeckle, Manuel Battegay, Michael Mayr, Maja Weisser   +6 more
doaj   +2 more sources

Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy

HIV/AIDS: Research and Palliative Care, 2015
Nils von Hentig HIV Center, Medical Department II, Hospital of the JW Goethe-University, Frankfurt, BAG Darab-Kaboly/von Hentig, General Medicine and HIV Care, Frankfurt am Main, Germany Abstract: The pharmacoenhancement of plasma concentrations of ...
von Hentig N
doaj   +1 more source

Data on the stability of darunavir/cobicistat suspension after tablet manipulation [PDF]

Data in Brief, 2020
The COVID-19 outbreak is now one of the most critical crises to manage for most of the national healthcare systems in the world. In the absence of authorised pharmacological treatments, many antiretrovirals, including darunavir/cobicistat fixed ...
D. Zanon, A. Manca, A. De Nicolò, A. D'Avolio, U.M. Musazzi, F. Cilurzo, N. Maximova, C. Tomasello, P. Minghetti   +8 more
doaj   +2 more sources

Iatrogenic Cushing’s Syndrome: The Result of Cobicistat and Glucocorticoid Interaction in an HIV Patient After Bariatric Surgery [PDF]

, 2023
Cobicistat, used as a pharmacokinetic booster in therapeutic combination with human immunodeficiency virus (HIV) protease inhibitors and integrase inhibitors, is a strong inhibitor of cytochrome P450 3A4 (CYP3A4).
Esteves Brandão, Maria, Benido Silva, Vânia, Mesquita, Isabel, Pereira, Maria Teresa, Cardoso, Joana   +4 more
core   +1 more source

Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV [PDF]

, 2021
OBJECTIVE: To evaluate darunavir and cobicistat pharmacokinetics during pregnancy compared to postpartum and in infant washout samples after delivery. DESIGN: Nonrandomized, open-label, parallel-group, multi-center phase-IV prospective study of darunavir
RUNGRUENGTHANAKIT, Kittipong, Mark Mirochnick, Kayla Denson, Mary E. Paul, Sandra Burchett, MOMPER, Jeremiah D., Best, Brookie M, Alice Stek, SHAPIRO, David E., David E. Shapiro, BEST, Brookie M., Jeremiah D. Momper, BURCHETT, Sandra, YANG, Derek, Yang, Derek Z, CAPPARELLI, Edmund V., WANG, Jiajia, Kathleen George, STEK, Alice, Capparelli, Edmund V, CHAKHTOURA, Nahida, DENSON, Kayla, Momper, Jeremiah D, Shapiro, David E, FEBO, Irma L., PAUL, Mary E., SMITH, Elizabeth, Jiajia Wang, Kittipong Rungruengthanakit, Nahida Chakhtoura, Gwendolyn B. Scott, Irma L. Febo, Brookie M. Best, Elizabeth Smith, Febo, Irma L, Derek Z. Yang, GEORGE, Kathleen, Edmund V. Capparelli, SCOTT, Gwendolyn B., Scott, Gwendolyn B, Paul, Mary E, MIROCHNICK, Mark   +41 more
core   +1 more source

Pharmacokinetics of Atazanavir Boosted With Cobicistat in Pregnant and Postpartum Women With HIV [PDF]

, 2022
BACKGROUND: This study evaluated atazanavir and cobicistat pharmacokinetics during pregnancy compared with postpartum and in infant washout samples. SETTING: A nonrandomized, open-label, parallel-group, multicenter prospective study of atazanavir and ...
Mark Mirochnick, George, Kathleen, Kayla Denson, Mary E. Paul, Kathleen M. Powis, Martina L. Badell, Best, Brookie M, Alice Stek, David E. Shapiro, Denson, Kayla, Jeremiah D. Momper, Kathleen George, Capparelli, Edmund V, Stek, Alice, Mirochnick, Mark, Powis, Kathleen M, Momper, Jeremiah D, Shapiro, David E, Renee Browning, Wang, Jiajia, Jiajia Wang, Browning, Renee, Kittipong Rungruengthanakit, Nahida Chakhtoura, Badell, Martina L, Brookie M. Best, Edmund V. Capparelli, Rungruengthanakit, Kittipong, Chakhtoura, Nahida, Paul, Mary E, Team, for the IMPAACT P1026s Protocol   +30 more
core   +1 more source

Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy

Clinical and Translational Science, 2023
Expression of CYP3A5 protein is a basal and acquired resistance mechanism of pancreatic ductal adenocarcinoma cells conferring protection against the CYP3A and CYP2C8 substrate paclitaxel through metabolic degradation.
Nicolas Hohmann, Martin Ronald Sprick, Moritz Pohl, Azaz Ahmed, Jürgen Burhenne, Marietta Kirchner, Lucian Le Cornet, Markus Kratzmann, Jacek Hajda, Albrecht Stenzinger, Karen Steindorf, Stefan Delorme, Heinz‐Peter Schlemmer, Sabine Riethdorf, Ron vanSchaik, Klaus Pantel, Jens Siveke, Thomas Seufferlein, Dirk Jäger, Walter E. Haefeli, Andreas Trumpp, Christoph Springfeld   +21 more
doaj   +1 more source

The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus

Informatics in Medicine Unlocked, 2021
Spike glycoprotein is essential for the reproduction of the SARS-CoV-2 virus, and its inhibition using already approved antiviral drugs may open new avenues for treatment of patients with the COVID-19 disease.
Draško Tomić, Davor Davidović, Attila Marcel Szasz, Melinda Rezeli, Boris Pirkić, Jozsef Petrik, Vesna Bačić Vrca, Vladimir Janđel, Tomislav Lipić, Karolj Skala, Josip Mesarić, Marija Milković Periša, Zorislav Šojat, Branka Medved Rogina   +13 more
doaj   +1 more source